Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies against multidrug-resistant tuberculosis.

R Loddenkemper1, D Sagebiel, A Brendel

  • 1German Central Committee against Tuberculosis, DZK, Lungenklinik Heckeshorn, Berlin. loddheck@zedat.fu-berlin.de

The European Respiratory Journal. Supplement
|August 10, 2002
PubMed
Summary

Multidrug-resistant tuberculosis (MDR-TB) is a growing global health threat, with millions infected and difficult treatment outcomes. Urgent strategies are needed to combat this resistant form of tuberculosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[125 Years German Central Committee for the Fight against Tuberculosis (DZK)].

Pneumologie (Stuttgart, Germany)·2020
Same author

Improving outcomes for lung disease in Africa.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

[Pulmonary Medicine and its Institutions During National Socialism].

Pneumologie (Stuttgart, Germany)·2018
Same author

Chemotherapy in bone and joint tuberculosis.

Der Orthopade·2017
Same author

[On the History and Future of Thoracoscopy].

Pneumologie (Stuttgart, Germany)·2016
Same author

Pneumologie (Stuttgart, Germany)·2016

Area of Science:

  • Public Health
  • Infectious Diseases
  • Microbiology

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global tuberculosis control efforts.
  • Defined by resistance to isoniazid and rifampicin, MDR-TB affects millions worldwide, with high prevalence in certain regions.

Purpose of the Study:

  • To highlight the escalating threat of MDR-TB globally.
  • To identify key risk factors and geographical hotspots associated with MDR-TB.
  • To emphasize the urgent need for improved treatment and prevention strategies.

Main Methods:

  • The study reviews global estimates of MDR-TB prevalence.
  • It identifies high-prevalence countries and regions.
  • Risk factors and treatment challenges are analyzed based on existing data.

Related Experiment Videos

Main Results:

  • In 2000, 273,000 MDR-TB cases occurred among 8.7 million new tuberculosis cases.
  • Estonia, China (Henan), Latvia, and Russia (Ivanovo, Tomsk Oblasts) reported high MDR-TB rates in 1998.
  • Risk factors include prior treatment, specific geographic origins, imprisonment, homelessness, and HIV co-infection.

Conclusions:

  • MDR-TB treatment is challenging, lengthy, expensive, and often unsuccessful.
  • Effective tuberculosis control programs and the judicious use of second-line drugs are crucial.
  • Developing new strategies is essential to defuse the 'ticking time bomb' of MDR-TB.